P
PHAR
Pharming Group N.V.
10.41
-0.36-3.34%Opening12:00 09/24 EDT
OPEN/PREV CLOSE9.75/9.75
TODAY RANGE9.74-10.08
VOL10.81K
MARKET CAP693.63M
52 WEEK RANGE9.62-21.34
AVG VOL (3M)22.88K
% TURNOVER0.02%
TURNOVER--
P/E (TTM)54.20
% RANGE3.53%
EPS(TTM)0.1808
P/E(FORWARD)21.30
P/B2.564
BVPS3.822
DIVIDEND--
P/S1.828
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP693.63M
SHARES OUTSTANDING70.78M
NEXT EARNINGS03/11-03/16
FREE FLOAT70.78M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·5d ago
Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes
TipRanks·6d ago
Pharming announces CEO Fabrice Chouraqui to step down
Seeking Alpha·6d ago
Pharming CEO Fabrice Chouraqui steps down
Seeking Alpha·6d ago
Biggest stock movers Tuesday: SMMT, NVTS, and more
NASDAQ·09/25 16:09
FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS
TipRanks·09/25 14:35
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
TipRanks·09/23 11:16
Canaccord Genuity Reaffirms Their Buy Rating on Pharming Group (PHAR)
Dow Jones·09/22 16:26
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Benzinga·09/22 16:16
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
TipRanks·09/22 16:00
Analysts’ Top Healthcare Picks: The Ensign Group (ENSG), Pharming Group (PHAR)
TipRanks·09/22 15:25
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
TipRanks·09/22 10:00
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
Seeking Alpha·09/14 14:47
U.S. 10 Year tops 5% for the first time since October of 2023
Same Industry
Name/Symbol
Change%
Price